HCA Healthcare (HCA) Stock May Be 49% Undervalued On Education Acquisition

HCA Healthcare has produced strong long term share returns. The key question now is whether a price near US$435 per share is still aligned with the cash flows the business can generate. With fresh legal disputes and a new education acquisition in the mix, investors are weighing how durable those cash flows look from here.

• Over the past 5 years, HCA Healthcare has delivered a total return of 83.3%, which puts real pressure on the underlying cash flows to justify how far the stock has already run.
• The recent acquisition of The College of Health Care Professions may support future staffing capacity and operating stability, which can influence both the level and reliability of cash flows used in a Discounted Cash Flow (DCF) estimate.
• What if you looked at HCA Healthcare through its earnings instead? See what HCA Healthcare's 13.8x P/E says about the price.

The issue now is whether HCA Healthcare's current share price is fully supported by its projected cash flows when viewed through a Discounted Cash Flow (DCF) lens.

If you want to stress test the same cash flow question you are asking of HCA Healthcare across a wider field, take a look at 32 high quality undervalued stocks

Does HCA Healthcare Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach here evaluates the cash HCA Healthcare can return to shareholders over time and then discounts it back to today. Latest twelve month free cash flow is about $6.0b, and the model assumes these owner earnings keep growing from that base rather than shrinking. That supports an intrinsic value estimate that the DCF framework indicates is substantially above the current share price of $435.61.

Projected free cash flows out toward 2030 stay in the multibillion dollar range, with growth slowing over time instead of relying on aggressive step changes. The acquisition of The College of Health Care Professions feeds into that story because it aims to support staffing pipelines and operating continuity, which matter a lot when cash flows are the main input to valuation. Despite the fresh lawsuit from Texas hospitals over denied claims adding a legal overhang, the market price still sits below what these projected cash flows suggest for HCA Healthcare. Find out what HCA Healthcare could be worth using our Discounted Cash Flow (DCF) estimate.

The HCA Healthcare Narrative: What Would Justify Today's Price?

Narratives pick up where the DCF puzzle for HCA Healthcare leaves off by spelling out which future paths for growth, margins and earnings would need to play out for the stock to look meaningfully cheaper or more expensive than today’s price. Each view ties its number to a concrete path for growth, profitability and risk, which gives you something specific to test as new operating data and legal or regulatory updates emerge on Simply Wall St’s Community page.

Community views on HCA Healthcare are split between those who see resilient scale and cash generation and those who focus on payer mix and execution risk.

Bull case: 31% undervalued

"HCA’s footprint is enormous. With hospitals, surgery centers, and outpatient facilities spread across the U.S., the company benefits from scale in ways smaller providers simply can’t match…"

Discover why this Narrative puts HCA Healthcare at 31% undervalued.

Bear case: 15% overvalued

"There is higher acuity in areas like cardiac care, trauma and rehab. However, payer mix shifts tied to exchanges, growth in uninsured equivalent admissions and slower Medicaid conversions could keep uncompensated care and patient balance collections elevated…"

Explore why this Narrative puts HCA Healthcare at 15% overvalued.

One more HCA Healthcare factor that can quietly shift the risk and reward

Even the cleanest cash flow model for HCA Healthcare rests on who is steering the hospital network and how their incentives line up with long term outcomes. See who runs HCA Healthcare and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com